Parameter
| Biomarker | TP53 (mutation) | Full name | Tumor protein p53 mutations | Molecular Type | Nucleic acid (DNA mutations) |
|---|---|---|---|---|---|
| Molecular Formula | Molecular Weight | Core Functional Dimensions | Diagnosis, prognosis, selection of targeted therapy | ||
| Disease | Cholangiocarcinoma (CCA) | Disease Subtypes | / | ||
| Organ | Bile duct/Liver | Test Sample / Technology Platform | Tissue/plasma/bile (NGS, Sanger sequencing) | ||
| Pathobiological Mechanisms | Mutations can lead to DNA damage repair defects, genome instability, accelerate tumor progression Mutations lead to the accumulation of 2-hydroxyglutaric acid (2-HG), inhibit cell differentiation, and promote tumorigenesis | ||||
| Clinical Availability Status | Clinical validation; One of the most common mutation types | ||||
| Notes and Dynamics | Detection rate was 38.1%, and the TuBianZhe may be sensitive to PARP inhibitors, HR pathway TuBianZhe survival was significantly shortened | ||||